Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements (Tables)

v3.19.1
Fair Value Measurements (Tables)
3 Months Ended
Mar. 31, 2019
Fair Value Disclosures [Abstract]  
Financial Assets and Liabilities Carried at Fair Value on Recurring Basis

The following tables set forth the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as follows (in thousands):

 

 

Fair Value Measurements at March 31, 2019 Using

 

 

 

Quoted Prices in

Active Markets for

Identical Assets

 

 

Significant Other

Observable

Inputs

 

 

Significant

Unobservable

Inputs

 

 

 

 

 

 

 

(Level 1)

 

 

(Level 2)

 

 

(Level 3)

 

 

Total

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Long-term equity securities

 

$

 

 

$

 

 

$

1,107

 

 

$

1,107

 

Liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Contingent consideration

 

$

 

 

$

 

 

$

75

 

 

$

75

 

 

 

 

 

Fair Value Measurements at December 31, 2018 Using

 

 

 

Quoted Prices in

Active Markets for

Identical Assets

 

 

Significant Other

Observable

Inputs

 

 

Significant

Unobservable

Inputs

 

 

 

 

 

 

 

(Level 1)

 

 

(Level 2)

 

 

(Level 3)

 

 

Total

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Long-term equity securities

 

$

 

 

$

 

 

$

392

 

 

$

392

 

Summary of Changes in Estimated Fair Value of Level 3 Financial Assets

The following table provides a summary of changes in the estimated fair value of the Company’s Level 3 financial assets for the three months ended March 31, 2019 (in thousands):

Balance at December 31, 2018

 

$

392

 

Change in fair value

 

 

715

 

Balance at March 31, 2019

 

$

1,107

 

Estimated Fair Value of Equity Securities Assumptions

The estimated fair value of the equity securities was calculated based on the following assumptions as of March 31, 2019:

Closing common stock price on the OTC exchange

 

$

0.20

 

 

 

 

 

 

Tranche 1:

 

 

 

 

Discount for lack of marketability

 

 

24

%

Estimated time to liquidity of shares

 

1 year

 

 

 

 

 

 

Tranche 2:

 

 

 

 

Discount for lack of marketability

 

 

35

%

Estimated time to liquidity of shares

 

2 years

 

The estimated fair value of the equity securities was calculated based on the following assumptions as of December 31, 2018:

Discount for lack of marketability

 

 

35

%

Estimated time to liquidity of shares

 

1.45 years

 

 

 

 

 

 

Scenario probabilities

 

 

 

 

Liquidation

 

 

20

%

Near-term sale

 

 

5

%

Near-term financing

 

 

75

%

Outstanding Long Term Debt Carrying Amount and Estimated Fair Value The carrying amount and the estimated fair value of the Company’s outstanding long-term debt at March 31, 2019, and December 31, 2018, are as follows (in thousands):

 

 

March 31, 2019

 

 

December 31, 2018

 

 

 

Carrying Amount

 

 

Fair Value

 

 

Carrying Amount

 

 

Fair Value

 

Novartis note

 

$

15,193

 

 

$

15,130

 

 

$

15,193

 

 

$

14,825

 

SVB Loan

 

 

7,390

 

 

 

7,388

 

 

 

7,286

 

 

 

7,281

 

Total

 

$

22,583

 

 

$

22,518

 

 

$

22,479

 

 

$

22,106